Treatment persistence and clinical outcomes following subcutaneous methotrexate initiation in patients with rheumatoid arthritis: a real-world observational study

Clicks: 9
ID: 332632
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #48 of 48 articles by views in modern rheumatology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
ABSTRACT Objectives This study aimed to evaluate treatment persistence and safety following subcutaneous methotrexate (MTX) initiation in Japanese patients with RA and to assess clinical outcomes among patients who directly switched from oral to subcutaneous MTX. Methods This retrospective study included 101 patients with RA who initiated subcutaneous MTX at our institution. Efficacy and safety were analysed in patients who switched from oral MTX due to adverse events. The primary endpoint was the 26-week retention rate of subcutaneous MTX. Results Gastrointestinal intolerance was the commonest reason for switching from oral to subcutaneous MTX. The overall retention rate was 87.1% (88/101). Among 88 patients who switched, the 26-week retention rate was 92.0% (81/88). During 26 weeks after switching, MTX dose increased in 46.6% (41/88). In patients not receiving biologic or targeted synthetic disease-modifying anti-rheumatic drugs at switching (n=50), the 26-week retention rate was 96.0% (48/50), and mean MTX dose increased (10.3±2.8 to 12.0±2.8 mg/week; p<0.0001). The Clinical Disease Activity Index improved by week 26 (13.2±10.1 to 8.2±7.8; p<0.0001), with 30.0% (15/50) achieving remission. Conclusions Switching from oral to subcutaneous MTX in patients with RA who are intolerant to oral MTX may enable continued treatment and dose optimization and be associated with improved disease activity.
Reference Key
openalex_W7222809074 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yusuke Miyazaki, Satoshi Kubo, Shunsuke Fukuyo, Ippei Miyagawa, Ayako Yamaguchi, Yurie Satoh, Yasuyuki Todoroki, Hiroaki Tanaka, Masanobu Ueno, Ryuichiro Kanda, Yuya Fujita, Hidenori Sakai, Shingo Nakayamada, Yoshiya Tanaka
Journal modern rheumatology
Year 2026
DOI
10.1093/mr/roag089
URL
https://doi.org/10.1093/mr/roag089
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.